Supplemental Material 4. Results of gender-stratified analysis of treatment outcomes in the year of registration among patients by tuberculosis history, 2011–2018

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Total** | **2011** | **2012** | **2013** | **2014** | **2015** | **2016** | **2017** | **2018** | ***p*-value** |
|  |  | **(n=300 117)** | **(n=46 694)** | **(n=44 981)** | **(n=40 738)** | **(n=38 386)** | **(n=35 220)** | **(n=33 930)** | **(n=30 997)** | **(n=29 171)** |
| New cases of tuberculosis patients |
| Men and women |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Treatment Success | 216 685 | (83.7) | 29 629 | (77.9) | 31 311 | (81.6) | 29 694 | (84.1) | 28 954 | (85.2) | 26 604 | (86.7) | 25 544 | (86.1) | 23 333 | (86) | 21 616 | (84.4) | <0.001 |
| Failure |  | 185 | (0.1) | 32 | (0.1) | 48 | (0.1) | 30 | (0.1) | 30 | (0.1) | 13 | (0) | 10 | (0) | 11 | (0) | 11 | (0) |  |
| Loss to follow-up | 9215 | (3.6) | 2004 | (5.3) | 1865 | (4.9) | 1514 | (4.3) | 1270 | (3.7) | 872 | (2.8) | 695 | (2.3) | 542 | (2) | 453 | (1.8) |  |
| TB-related death during treatment | 4500 | (1.7) | 469 | (1.2) | 474 | (1.2) | 538 | (1.5) | 649 | (1.9) | 636 | (2.1) | 667 | (2.2) | 528 | (1.9) | 539 | (2.1) |  |
| Other death during treatment | 17 502 | (6.8) | 1425 | (3.7) | 1924 | (5) | 1886 | (5.3) | 2270 | (6.7) | 2345 | (7.6) | 2536 | (8.5) | 2515 | (9.3) | 2601 | (10.2) |  |
| Not evaluated | 10 049 | (3.9) | 4383 | (11.5) | 2670 | (7) | 1592 | (4.5) | 736 | (2.2) | 157 | (0.5) | 119 | (0.4) | 118 | (0.4) | 274 | (1.1) |  |
| Missing data | 631 | (0.2) | 71 | (0.2) | 56 | (0.1) | 59 | (0.2) | 84 | (0.2) | 71 | (0.2) | 94 | (0.3) | 88 | (0.3) | 108 | (0.4) |  |
| Men |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Treatment Success | 122 016 | (82.3) | 16 405 | (75.8) | 17 521 | (79.8) | 16 666 | (82.8) | 16 185 | (83.6) | 15 162 | (85.4) | 14 535 | (85.1) | 13 177 | (85.1) | 12 365 | (83.6) | <0.001 |
| Failure |  | 146 | (0.1) | 21 | (0.1) | 38 | (0.2) | 25 | (0.1) | 22 | (0.1) | 11 | (0.1) | 9 | (0.1) | 9 | (0.1) | 11 | (0.1) |  |
| Loss to follow-up | 6036 | (4.1) | 1292 | (6) | 1222 | (5.6) | 967 | (4.8) | 834 | (4.3) | 577 | (3.3) | 485 | (2.8) | 362 | (2.3) | 297 | (2) |  |
| TB-related death during treatment | 2713 | (1.8) | 273 | (1.3) | 293 | (1.3) | 346 | (1.7) | 394 | (2) | 376 | (2.1) | 387 | (2.3) | 324 | (2.1) | 320 | (2.2) |  |
| Other death during treatment | 10 699 | (7.2) | 893 | (4.1) | 1224 | (5.6) | 1143 | (5.7) | 1418 | (7.3) | 1468 | (8.3) | 1521 | (8.9) | 1485 | (9.6) | 1547 | (10.5) |  |
| Not evaluated | 6209 | (4.2) | 2717 | (12.6) | 1640 | (7.5) | 942 | (4.7) | 456 | (2.4) | 113 | (0.6) | 85 | (0.5) | 74 | (0.5) | 182 | (1.2) |  |
| Missing data | 389 | (0.3) | 38 | (0.2) | 28 | (0.1) | 43 | (0.2) | 56 | (0.3) | 44 | (0.2) | 56 | (0.3) | 54 | (0.3) | 70 | (0.5) |  |
| Women |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Treatment Success | 94 669 | (85.6) | 13 224 | (80.8) | 13 790 | (84.2) | 13 028 | (85.8) | 12 769 | (87.3) | 11 442 | (88.4) | 11 009 | (87.5) | 10 156 | (87.2) | 9251 | (85.6) | <0.001 |
| Failure |  | 39 | (0) | 11 | (0.1) | 10 | (0.1) | 5 | (0) | 8 | (0.1) | 2 | (0) | 1 | (0) | 2 | (0) | 0 | (0) |  |
| Loss to follow-up | 3179 | (2.9) | 712 | (4.3) | 643 | (3.9) | 547 | (3.6) | 436 | (3) | 295 | (2.3) | 210 | (1.7) | 180 | (1.5) | 156 | (1.4) |  |
| TB-related death during treatment | 1787 | (1.6) | 196 | (1.2) | 181 | (1.1) | 192 | (1.3) | 255 | (1.7) | 260 | (2) | 280 | (2.2) | 204 | (1.8) | 219 | (2) |  |
| Other death during treatment | 6803 | (6.2) | 532 | (3.2) | 700 | (4.3) | 743 | (4.9) | 852 | (5.8) | 877 | (6.8) | 1015 | (8.1) | 1030 | (8.8) | 1054 | (9.8) |  |
| Not evaluated | 3840 | (3.5) | 1666 | (10.2) | 1030 | (6.3) | 650 | (4.3) | 280 | (1.9) | 44 | (0.3) | 34 | (0.3) | 44 | (0.4) | 92 | (0.9) |  |
| Missing data　 | 242 | (0.2) | 33 | (0.2) | 28 | (0.2) | 16 | (0.1) | 28 | (0.2) | 27 | (0.2) | 38 | (0.3) | 34 | (0.3) | 38 | (0.4) |  |
| Previously treated patients with tuberculosis |
| Men and women |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Treatment Success | 30 883 | (74.7) | 5741 | (66.1) | 4914 | (74.1) | 4195 | (77.3) | 3472 | (79) | 3548 | (78.5) | 3341 | (78.3) | 2992 | (77.5) | 2680 | (75.1) | <0.001 |
| Failure |  | 123 | (0.3) | 38 | (0.4) | 33 | (0.5) | 16 | (0.3) | 10 | (0.2) | 11 | (0.2) | 7 | (0.2) | 2 | (0.1) | 6 | (0.2) |  |
| Loss to follow-up | 3168 | (7.7) | 879 | (10.1) | 487 | (7.3) | 393 | (7.2) | 281 | (6.4) | 339 | (7.5) | 289 | (6.8) | 262 | (6.8) | 238 | (6.7) |  |
| TB-related death during treatment | 975 | (2.4) | 191 | (2.2) | 123 | (1.9) | 115 | (2.1) | 114 | (2.6) | 135 | (3) | 104 | (2.4) | 91 | (2.4) | 102 | (2.9) |  |
| Other death during treatment | 2878 | (7) | 367 | (4.2) | 327 | (4.9) | 321 | (5.9) | 322 | (7.3) | 358 | (7.9) | 419 | (9.8) | 387 | (10) | 377 | (10.6) |  |
| Not evaluated | 3065 | (7.4) | 1411 | (16.3) | 713 | (10.7) | 360 | (6.6) | 167 | (3.8) | 107 | (2.4) | 71 | (1.7) | 96 | (2.5) | 140 | (3.9) |  |
| Missing data | 258 | (0.6) | 54 | (0.6) | 36 | (0.5) | 25 | (0.5) | 27 | (0.6) | 24 | (0.5) | 34 | (0.8) | 32 | (0.8) | 26 | (0.7) |  |
| Men |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Treatment Success | 21 109 | (72.8) | 3912 | (63.8) | 3293 | (71.8) | 2828 | (75.4) | 2394 | (76.7) | 2402 | (76.4) | 2308 | (76.8) | 2081 | (76.2) | 1891 | (74.7) | <0.001 |
| Failure |  | 91 | (0.3) | 28 | (0.5) | 25 | (0.5) | 10 | (0.3) | 6 | (0.2) | 10 | (0.3) | 6 | (0.2) | 2 | (0.1) | 4 | (0.2) |  |
| Loss to follow-up | 2400 | (8.3) | 677 | (11) | 379 | (8.3) | 297 | (7.9) | 234 | (7.5) | 254 | (8.1) | 210 | (7) | 192 | (7) | 157 | (6.2) |  |
| TB-related death during treatment | 768 | (2.6) | 162 | (2.6) | 98 | (2.1) | 97 | (2.6) | 88 | (2.8) | 103 | (3.3) | 75 | (2.5) | 65 | (2.4) | 80 | (3.2) |  |
| Other death during treatment | 2246 | (7.7) | 282 | (4.6) | 254 | (5.5) | 263 | (7) | 250 | (8) | 282 | (9) | 336 | (11.2) | 295 | (10.8) | 284 | (11.2) |  |
| Not evaluated | 2202 | (7.6) | 1031 | (16.8) | 512 | (11.2) | 241 | (6.4) | 127 | (4.1) | 75 | (2.4) | 48 | (1.6) | 71 | (2.6) | 97 | (3.8) |  |
| Missing data | 182 | (0.6) | 38 | (0.6) | 23 | (0.5) | 15 | (0.4) | 22 | (0.7) | 17 | (0.5) | 23 | (0.8) | 26 | (1) | 18 | (0.7) |  |
| Women |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Treatment Success | 9774 | (79.1) | 1829 | (71.7) | 1621 | (79.1) | 1367 | (81.7) | 1078 | (84.7) | 1146 | (83.1) | 1033 | (82) | 911 | (80.6) | 789 | (76) | <0.001 |
| Failure |  | 32 | (0.3) | 10 | (0.4) | 8 | (0.4) | 6 | (0.4) | 4 | (0.3) | 1 | (0.1) | 1 | (0.1) | 0 | (0) | 2 | (0.2) |  |
| Loss to follow-up | 768 | (6.2) | 202 | (7.9) | 108 | (5.3) | 96 | (5.7) | 47 | (3.7) | 85 | (6.2) | 79 | (6.3) | 70 | (6.2) | 81 | (7.8) |  |
| TB-related death during treatment | 207 | (1.7) | 29 | (1.1) | 25 | (1.2) | 18 | (1.1) | 26 | (2) | 32 | (2.3) | 29 | (2.3) | 26 | (2.3) | 22 | (2.1) |  |
| Other death during treatment | 632 | (5.1) | 85 | (3.3) | 73 | (3.6) | 58 | (3.5) | 72 | (5.7) | 76 | (5.5) | 83 | (6.6) | 92 | (8.1) | 93 | (9) |  |
| Not evaluated | 863 | (7) | 380 | (14.9) | 201 | (9.8) | 119 | (7.1) | 40 | (3.1) | 32 | (2.3) | 23 | (1.8) | 25 | (2.2) | 43 | (4.1) |  |
| Missing data | 76 | (0.6) | 16 | (0.6) | 13 | (0.6) | 10 | (0.6) | 5 | (0.4) | 7 | (0.5) | 11 | (0.9) | 6 | (0.5) | 8 | (0.8) |  |